Share this article on:

Carpal Tunnel Syndrome after Xiaflex Injection for Dupuytren Disease

Shubinets, Valeriy M.D.; Lin, Ines C. M.D.; Chang, Benjamin M.D.

Plastic & Reconstructive Surgery: April 2017 - Volume 139 - Issue 4 - p 1031e–1032e
doi: 10.1097/PRS.0000000000003163
Viewpoints

Division of Plastic Surgery, University of Pennsylvania Health System, Philadelphia, Pa.

Correspondence to Dr. Chang, Division of Plastic Surgery, Department of Surgery, University of Pennsylvania, Perelman Center for Advanced Medicine, 3400 Civic Center Boulevard, South Pavilion, Seventh Floor, Philadelphia, Pa. 19104, changb@uphs.upenn.edu

Back to Top | Article Outline

Sir:

Marketed under the name Xiaflex (Endo Pharmaceuticals, Inc., Washington, D.C.), collagenase Clostridium histolyticum represents a safe and efficacious nonsurgical treatment of Dupuytren disease.1,2 Dupuytren disease is a fibroproliferative disorder of hand palmar fascia that leads to formation of disfiguring pathologic cords and flexion contractures.3 When Xiaflex is injected into the cord, it lyses the cord’s collagen; the following day, extension force is applied to the affected finger, rupturing the cord.1 Most patients experience mild adverse reactions such as local edema, bruising, and pain. Major reactions such as flexor tendon ruptures (0.3 percent) and complex regional pain syndrome (0.1 percent) are rare.4,5 In this communication, we describe a case of a patient treated with Xiaflex for Dupuytren contracture of the ring finger who subsequently developed a severe, subacute carpal tunnel syndrome, a previously undescribed side effect of Xiaflex.

The patient was a healthy 63-year-old man who presented with recurrent right ring finger proximal interphalangeal joint contracture (67 degrees). He had prior Xiaflex treatment in the same digit 4 years previously. A repeated injection of Xiaflex (0.58 mg) between the metacarpophalangeal and proximal interphalangeal joint creases was performed by means of standard protocol. The following day, extension force was applied to rupture the cord and achieve a 47-degree improvement in proximal interphalangeal joint flexion. The patient’s subsequent recovery was uneventful with the exception that, at the 2-month visit, he complained of tingling and numbness in the radial three digits, along with nighttime awakenings. He was started on a wrist cock-up splint at night. At the 4-month visit, he noted weakness in his right hand and difficulty buttoning his shirt. Electromyography revealed abundant fibrillation potentials and positive sharp waves in the abductor pollicis brevis, with a severely decreased number of motor units but normal motor unit morphology. Nerve conduction velocity study demonstrated absent median sensory nerve response (Table 1). Motor response had very low amplitude and prolonged distal latency (Table 2). These findings were consistent with very severe, subacute median neuropathy at the wrist, and the patient ultimately underwent open carpal tunnel release. Two months postoperatively, he has already experienced significant relief of tingling and nighttime awakening. He still has some residual numbness, which is expected given the severity of his carpal tunnel syndrome. He continues to do well in terms of Dupuytren contracture and has maintained his improved ring finger range of motion.

To our knowledge, this is the first report of carpal tunnel syndrome following Xiaflex injection. It is unlikely that the collagenase mix itself led to carpal tunnel syndrome, as the injection was very distal to the carpal tunnel. We suspect the primary causative factor was the swelling, which is very common following Xiaflex injection.1,4 The patient may have had subclinical carpal tunnel syndrome and the swelling from the Xiaflex treatment pushed him to develop symptoms. Given the scenario, we have since raised the question of whether Dupuytren patients would benefit from carpal tunnel syndrome screening before Xiaflex injection. Electromyography/nerve conduction velocity studies may not be necessary, but a thorough history and physical examination are likely warranted. Even if asymptomatic, provocative maneuvers such as Phalen and Durkan tests may help identify patients at risk and appropriately direct treatment.

Back to Top | Article Outline

DISCLOSURE

The authors have no financial interest to declare in relation to the content of this article.

Valeriy Shubinets, M.D.

Ines C. Lin, M.D.

Benjamin Chang, M.D.

Division of Plastic Surgery

University of Pennsylvania Health System

Philadelphia, Pa.

Back to Top | Article Outline

REFERENCES

1. Desai SS, Hentz VRThe treatment of Dupuytren disease. J Hand Surg Am. 2011;36:936–942.
2. Warwick D, Arandes-Renú JM, Pajardi G, Witthaut J, Hurst LCCollagenase Clostridium histolyticum: Emerging practice patterns and treatment advances. J Plast Surg Hand Surg. 2016;50:251–261.
3. Eaton CEvidence-based medicine: Dupuytren contracture. Plast Reconstr Surg. 2014;133:1241–1251.
4. Peimer CA, Wilbrand S, Gerber RA, Chapman D, Szczypa PPSafety and tolerability of collagenase Clostridium histolyticum and fasciectomy for Dupuytren’s contracture. J Hand Surg Eur Vol. 2015;40:141–149.
5. Gaston RG, Larsen SE, Pess GM, et alThe efficacy and safety of concurrent collagenase Clostridium histolyticum injections for 2 Dupuytren contractures in the same hand: A prospective, multicenter study. J Hand Surg Am. 2015;40:1963–1971.
Back to Top | Article Outline

GUIDELINES

Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:

* Text—maximum of 500 words (not including references)

* References—maximum of five

* Authors—no more than five

* Figures/Tables—no more than two figures and/or one table

Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS’ enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.

We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.

The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.

©2017American Society of Plastic Surgeons